Try our Advanced Search for more refined results

King Drug Co of Florence Inc, et al v. Smithkline Beecham Corporation, et al

  1. July 17, 2014

    FTC Looks To Join Lamictal Pay-For-Delay Oral Args

    The Federal Trade Commission on Wednesday sought to participate in oral arguments at the Third Circuit as it considers whether the U.S. Supreme Court's recent pay-for-delay ruling applies to no-authorized-generic settlements amid a class action case over GlaxoSmithKline PLC's Lamictal.

  2. June 16, 2014

    Lamictal Buyers Urge 3rd Circ. To Revive Pay-For-Delay Case

    Drug purchasers challenging a no-authorized-generic settlement between GlaxoSmithKline PLC and Teva Pharmaceutical Industries ltd. told the Third Circuit on Friday that the U.S. Supreme Court's recent pay-for-delay ruling didn't create a new safe haven for some kinds of pharmaceutical patent settlements.

  3. May 02, 2014

    State AGs Urge 3rd Circ. To Reverse Pay-For-Delay Ruling

    The attorneys general of 28 states urged the Third Circuit in an amicus brief Thursday to reverse a ruling that a U.S. Supreme Court decision on pay-for-delay agreements only applies to direct cash payment, warning the ruling would encourage companies to conceal the value of the payments with complicated side deals.

  4. April 29, 2014

    Actavis Standard Transcends Cash Deals, FTC Tells 3rd Circ.

    The Federal Trade Commission on Monday urged the Third Circuit to revive a proposed antitrust class action against GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. over a deal to postpone generics of epilepsy drug Lamictal, arguing that cash isn't the only form of compensation prohibited under a recent U.S. Supreme Court ruling on pay-for-delay agreements.